NCT05743140

Brief Summary

Coronary microvascular dysfunction (CMD) carries an increased risk of adverse cardiovascular clinical outcomes. The association between fundus microcirculation changes and coronary microcirculation is not well understood. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus microcirculation. In this study, investigators intend to use the coronary angiography-derived index of microvascular resistance (caIMR) to screen patients with CMD, explore the relationship between relevant parameters based on OCT and OCTA measurements and caIMR, and evaluate the feasibility and clinical value of non-invasive identification of CMD through fundus OCT and OCTA.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 24, 2023

Completed
5 days until next milestone

Study Start

First participant enrolled

March 1, 2023

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2025

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

August 12, 2025

Status Verified

August 1, 2025

Enrollment Period

2.8 years

First QC Date

February 7, 2023

Last Update Submit

August 7, 2025

Conditions

Keywords

coronary microvascular diseaseCaIMROCTOCTAFundus microcirculation

Outcome Measures

Primary Outcomes (1)

  • Diagnostic accuracy of fundus OCT and OCTA examinations for coronary microvascular disease

    Investigators intend to use these indicators to assess the diagnostic accuracy of fundus OCT and OCTA for CMD: area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio.

    2023.3-2024.5

Study Arms (1)

CMD group, Non-CMD group

CMD group: participants whose CaIMR shows ≥25U. Non-CMD group: participants whose CaIMR less than 25U.

Diagnostic Test: CaIMR

Interventions

CaIMRDIAGNOSTIC_TEST

Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.

Also known as: OCT, OCTA
CMD group, Non-CMD group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Department of Cardiology, Peking University First Hospital

You may qualify if:

  • Patients who underwent coronary angiography in the Department of Cardiology, Peking University First Hospital;
  • Complete baseline clinical information;
  • Subject who have coronary angiography results, which shows coronary stenosis \< 50%;
  • Older than 18 years;
  • Subjects who have signed informed consent.

You may not qualify if:

  • Present serious fundus disease
  • Severe cataract and other ophthalmic diseases, which affect imaging quality;
  • Target coronary vessels provide collateral circulation for chronic complete occlusive lesions;
  • The target coronary angiography agent is poorly filled, overlapped, or severely distorted, and cannot fully expose the location of the lesion;
  • Coronary angiography images are of poor quality and cannot be identified;
  • Active bleeding state;
  • Severe renal insufficiency, contrast agent allergy, and unable to perform coronary angiography.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking university first hospital

Beijing, Beijing Municipality, 10034, China

RECRUITING

MeSH Terms

Conditions

Microvascular Angina

Condition Hierarchy (Ancestors)

Angina PectorisMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Bo Zheng, Dr

    Peking University First Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate professor

Study Record Dates

First Submitted

February 7, 2023

First Posted

February 24, 2023

Study Start

March 1, 2023

Primary Completion

December 12, 2025

Study Completion

January 1, 2026

Last Updated

August 12, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations